AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 262 min read$ALAB

Mayer Bethany sold $271K of ALAB

Mayer Bethany sold 686 shares of Astera Labs, Inc. (ALAB) at an average of $395.04 ($391.27–$399.96, $0.27M total) across 6 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mayer Bethany
Published Jun 26, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
high confidence
Mentioned
$ALAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size ($270,998.90) and that it was executed under a pre-arranged 10b5-1 plan; no new guidance, contracts, or regulatory actions are mentioned.

02

Market read

Traders may note insider selling for sentiment/positioning, but the 10b5-1 framing limits fundamental read-through.

03

What to watch

The disclosure aggregates multiple trades across a narrow price band, which can reduce interpretability versus a single large, non-plan sale.

Relevance 3/10Novelty 3/10Timing: after-hours/filing time (filed 2026-06-26) for ALAB insider-sale monitoring

Background

The article is an SEC Form 4 insider transaction for Astera Labs, Inc. (ALAB) filed on 2026-06-26, covering sales executed on 2026-06-24.

Company-level read

Ticker impact

$ALABNeutralHigh confidence
Context

Astera Labs director Mayer Bethany sold $270,998.90 of ALAB shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and it provides no new company-specific operational or financial information.

Market effects

Sector

Minimal; insider-sale Form 4s typically do not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • public_company
    Astera Labs, Inc.

    Issuer of the insider transaction disclosed on SEC Form 4 (ALAB).

  • insider
    Mayer Bethany

    Director who sold 686 shares across six trades under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALAB insider trading history →

Related articles

OCT 9
$ALABMed

Astera Labs Stock Fell 9% in a Day as an OpenAI Revenue Report Hit Chip Stocks. Here’s Where the Stock Could Go by 2030

Astera Labs (ALAB) stock dropped 9.21% to $347.05 on October 8, following a broader chip sector sell-off triggered by OpenAI's lower-than-expected revenue report. The company launched Aries 7, its PCIe 7 signal conditioning portfolio. Despite a 23% rise in 2026 revenue forecasts to $1.91B, free cash flow fell 49.6% YoY to $67.21M, raising concerns. Analysts' target prices range from $390 to $850, with a potential total return of 146%.

finance.yahoo.com2 min
OCT 7
$ALABMed

Why is Astera Labs stock sliding today?

Astera Labs (ALAB) stock dropped 5.0% after Zacks Research downgraded it from 'strong buy' to 'hold', following a 10% surge on S&P 500 inclusion speculation. Insider selling and high valuation also pressured the stock, with broader market declines adding to the downturn. Competitors like Marvell Technology intensify the competitive landscape. The stock remains sensitive to macroeconomic factors and analyst commentary.

investing.com2 min
OCT 6
$ALABHigh

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 9.5% to $396.82, with traders anticipating its inclusion in the S&P 500. The company reported Q2 revenue of $392.4M, beating estimates, and guided Q3 revenue to $540M–$560M. Analysts, including Fubon, have upgraded the stock, with a $500 price target. The S&P 500 and Nasdaq each rose 0.7% today.

investing.com2 min
SEP 16
$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

stockstotrade.com2 min
SEP 16
$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.

theglobeandmail.com2 min